You are here
Pipeline Insights of Bronchopulmonary Dysplasia, H1 2020: Therapeutics Assessment, Drug Profiles, Companies Involved
DUBLIN, March 24, 2020 /PRNewswire/ -- The "Bronchopulmonary Dysplasia - Pipeline Review, H1 2020" report has been added to ResearchAndMarkets.com's offering.
This pipeline guide provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 1 molecules, respectively.
Bronchopulmonary Dysplasia (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bronchopulmonary Dysplasia (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bronchopulmonary Dysplasia (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory)
Key Topics Covered
- Report Coverage
- Bronchopulmonary Dysplasia - Overview
- Bronchopulmonary Dysplasia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Bronchopulmonary Dysplasia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bronchopulmonary Dysplasia - Drug Profiles
- Bronchopulmonary Dysplasia - Dormant Projects
- Bronchopulmonary Dysplasia - Discontinued Products
- Bronchopulmonary Dysplasia - Product Development Milestones
Featured News & Press Releases
- Aug 23, 2019: Medipost's Pneumostem gets FDA's fast-track designation
- May 15, 2019: Meridigen new Neonatal Stem Cell Drug received TFDA Approval for Clinical Trial
- May 09, 2019: New phase 2b analysis suggests AEROSURF may reduce incidence and severity of bronchopulmonary dysplasia in preterm infants with RDS
- Feb 27, 2019: Esperite N.V. with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of bronchopulmonary dysplasia.
- Dec 10, 2018: New data from the AEROSURF phase 2b clinical program shows AEROSURF appears to reduce incidence and severity of Bronchopulmonary Dysplasia in preterm infants with RDS
- Nov 06, 2018: Esperite Group with The Cell Factory expands its extracellular vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmonary Dysplasia
- Aug 24, 2018: Airway Therapeutics announces appointment of chief medical officer
- May 03, 2016: MEDIPOST receives US Patent for PNEUMOSTEM' for Treating Lung Disease
- Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung
- Aug 12, 2014: MediPost, lung disease stem cell treatment drug 'Pneumostem' application for US clinical trial
- Jul 29, 2014: Lung disease stem cell drug designated orphan drug in development stage
- Feb 06, 2014: Stem cells to treat lung disease in preterm infants
- Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem
- May 31, 2012: Medipost Submits Application To KFDA For Pneumostem Clinical Trial
Companies Involved in Therapeutics Development
- Advent Therapeutics Inc
- Airway Therapeutics LLC
- Ayuvis Research Inc
- Chiesi Farmaceutici SpA
- Insmed Inc
- MediPost Co Ltd
- Meridigen Biotech Co Ltd
- Orphanix GmbH
- Radikal Therapeutics Inc
- Syntrix Biosystems Inc
- Takeda Pharmaceutical Co Ltd
- The Cell Factory BVBA
- Trimunocor Ltd
- United Therapeutics Corp
- Windtree Therapeutics Inc
For more information about this report visit https://www.researchandmarkets.com/r/ogw9aw
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets